On July 30, 2019, a flexible portfolio of small molecule inhibitors targeted for cancer immunotherapy research has made its debut in BOC Sciences, a New York-based chemical vendor that specializes in supply of various bio-chemicals like APIs, metabolites, impurities, ADCs, pharmaceutical excipients, intermediates and more.
On July 30, 2019, a flexible portfolio of small molecule inhibitors targeted for cancer immunotherapy research has made its debut in BOC Sciences, a New York-based chemical vendor that specializes in supply of various bio-chemicals like APIs, metabolites, impurities, ADCs, pharmaceutical excipients, intermediates and more.
Small molecule inhibitors are an already well-established class of potential useful drugs that can be applied in nearly all kinds of medical and pharmaceutical researches engaged with neurological disease, infection, cardiovascular disease, cancer, and metabolic disease; while immunotherapy is a type of cancer treatment designed to eradicate disseminated cancer by harnessing the potential of the immune system. This therapy has gained attention and recognition worldwide ever since its advent.
“Immunotherapy can be broadly subdivided into two categories: non-antigen-specific and antigen-specific. Non-antigen-specific strategies include nonspecific immune stimulation and immune checkpoint inhibitors, whereas antigen-specific strategies include various therapeutic vaccination approaches like CAR-T, “says Mr. Barron Jones, the Marketing Chief of BOC Sciences. “In the past decade, small molecules drive big improvements in immuno-oncology therapies. In order to improve clinical response rates, researchers are looking for novel combination regimens and checkpoint inhibitors come to rescue as a backbone in this treatment.”
The benefits of small molecules inhibitors are evident. First, they are able to cross cellular membranes and other barriers, thereby reaching intracellular targets easily. Second, their ability to achieve efficacy after oral administration allows for more flexibility within the treatment regimen as they typically have half-lives of less than 24 hours.
The majority of the novel second and third-generation of small molecule drugs are currently in preclinical or early-stage clinical development, mainly acting on intracellular targets and receptors that affect immuno-modulatory pathways in cancer. Below are the most popular immune checkpoint targets found on T cells or cancer cells:
•IDO • TDO• PD-1• PD-L1• CTLA4• CD28• B7-H4 (also known as B7‑S1, B7x and VCTN1)• KIR• 4-1BB(also known as CD137)• OX40 (also known as CD134)• LAG3• B7‑H3(also known as CD276)• TIM3• TIGIT• BTLA• VISTA• ICOS• CD39• CD27• CD30 (also known as TNFRSF8)• HHLA2 • Galectins
All these inhibitors are now readily available at BOC Sciences. For more information, please visit: https://www.bocsci.com/tag/
About BOC Sciences
In addition to supplying varieties of chemicals and reagents, BOC Sciences also strives to offer strategies and solutions to assist in the resolution of the industry’s most pressing drug development issues. To this end, it provides comprehensive drug discovery services including Virtual Screening, Drug Design, Screening Libraries, Compound Screening Platform, Formulation Service, Isotope Labeling Service, Fluorine Chemistry Service, etc.